
|Articles|February 1, 2005
Studies confirm utility of fixed-combination glaucoma drug
New Orleans—Twice-daily administration of a fixed-combination product containing brimonidine 0.2% plus timolol 0.5% (Combigan, Allergan Inc.) safely and effectively lowers IOP, according to the pooled results of two 12-month, randomized, double-masked, phase III studies.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Midyear cataract check-in: What 2026 has brought to the OR and beyond
2
Recognizing biomarkers of Alzheimer Disease using OCTA
3
Durability With Aflibercept 8 mg in Retinal Vascular Diseases
4
Next-Generation Anti-VEGF Therapies in Retinal Vascular Diseases
5





















